Vonicog alfa
Vonicog alfa, sold under the brand names Vonvendi and Veyvondi, is a medicine used to control bleeding in adults with von Willebrand disease. It is a recombinant von Willebrand factor.
The most common adverse reactions are generalized itching, vomiting, nausea, dizziness, and vertigo.
Vonicog alfa should not be used in the treatment of Hemophilia A.
In the UK it is available only via a named patient access program.
Vonicog alfa was approved for use in the United States in December 2015, and for use in the European Union in August 2018. It was granted orphan drug designations in both the United States and the European Union.
